@bpaigea's estrogen advice raises some red flags

What did @bpaigea actually say?

The short version: if you feel bad on HRT, the problem is probably too little estrogen, not too much, and you should ask your doctor to raise your dose. She walks through patch dosing math, argues that transdermal estradiol is bioidentical regardless of manufacturer, and closes with a sweeping claim that "there is absolutely zero increase in your risk profile for any major disease based upon the dose of estrogen that you take." That last sentence is the one that deserves the most scrutiny.

She also tells viewers to avoid oral estrogen unless a doctor can give them a specific reason, and uses pregnancy estrogen levels (roughly 6,000 pg/mL) to argue that standard HRT doses are essentially trivial by comparison.

Does the science back this up?

Partially, yes. The claim that transdermal estradiol carries a lower risk profile than oral estrogen is well-supported. The pregnancy comparison is scientifically sloppy but not dangerous. The "zero risk at any dose" line, though, is flatly not how the evidence works.

On the transdermal vs. oral question, she is on solid ground. A large observational study by Renoux et al. (2010, BMJ) found that oral estrogen, but not transdermal estradiol, was associated with increased risk of venous thromboembolism. The ESTHER study (Canonico et al., 2007, Circulation) confirmed this pattern. Transdermal routes bypass first-pass liver metabolism, which is the mechanism behind the clot risk difference. That is not a fringe position; it is mainstream clinical guidance from the British Menopause Society and reflected in ACOG recommendations.

The patch dosing arithmetic she describes, that a 0.05 mg patch raises serum estradiol by roughly 50 pg/mL, is a reasonable approximation of manufacturer labeling data and pharmacokinetic studies, though actual absorption varies considerably by skin site, age, and body composition (Stanczyk et al., 2013, Menopause).

What did they get wrong (or right)?

The bioidentical framing is mostly right, but slightly oversimplified. She correctly points out that transdermal products from large pharmaceutical companies, like Vivelle-Dot or Climara, contain 17-beta estradiol, which is structurally identical to endogenous estrogen. The word "bioidentical" has been so thoroughly weaponized by compounding pharmacy marketing that it is worth being precise: FDA-approved transdermal patches are bioidentical. Full stop. Credit where it is due.

The pregnancy estrogen argument is where things get sloppy. Comparing HRT doses to pregnancy levels is a rhetorical move, not a pharmacological argument. Pregnancy involves a completely different hormonal milieu, including massive progesterone concentrations, different receptor sensitivity, and placental physiology. Using 6,000 pg/mL as a "see, you will be fine" benchmark tells us nothing useful about risk at HRT doses.

The most problematic claim is the "absolutely zero increase in your risk profile" statement. This is not what the evidence says. Estrogen-only therapy in women with a uterus without progestogen opposition increases endometrial cancer risk in a dose-dependent manner (Grady et al., 1995, NEJM). Even in the transdermal context, dose is not clinically irrelevant.

What should you actually know?

Transdermal estradiol is genuinely the safer delivery route for most women, and underdosing is a real clinical problem that gets less attention than it should. But "safer than oral" does not mean "risk-free at any dose," and that distinction matters.

If you have a uterus and are on estrogen therapy, you need progestogen to protect the endometrial lining. Dose of estrogen is not irrelevant to that calculation. The PEPI trial (Writing Group for the PEPI Trial, 1995, JAMA) showed endometrial hyperplasia rates climbing significantly with unopposed estrogen, even at standard doses.

The practical takeaway from this video, that feeling unwell on HRT sometimes means your dose needs adjusting upward rather than stopping entirely, is clinically legitimate and honestly underappreciated. But "ask your doctor" is the right mechanism for that conversation, not a TikTok video telling you there is zero risk from taking more. Dose decisions belong in a clinical encounter where your history, your labs, and your uterine status are all part of the picture.